Bethesda, MD – MHRP is part of two multi-institution research teams, or “Collaboratories”, that were awarded funds from NIH to develop an integrated approach to finding an HIV cure. These research projects bring together some of the leading researchers in the cure field and will help advance strategies to induce HIV remission.
Prolonged COVID-19 infection among immune compromised individuals may generate multiple mutations of SARS-CoV-2 providing a path to more transmissible or virulent variants of concern. Researchers describe some implications of SARS-CoV-2 evolution in immunosuppressed patients in a new commentary in the New England Journal of Medicine.
Scientists at the Walter Reed Army Institute of Research recently published findings from a pre-clinical vaccine study aimed at providing protection from the physiological effects of heroin and fentanyl.
The U.S. Army Medical Research and Development Command (USAMRDC) selected the Army Liposome Formulation with QS21 (ALFQ) as one of the 2020 award recipients. ALFQ was developed by MHRP at Walter Reed Army Institute of Research (WRAIR) scientists and was awarded a patent in 2019. This Army-owned and developed adjuvant, ALFQ, has shown to be strongly potent as a vaccine adjuvant in preclinical studies.
A recent study that sought to characterize the structure and genetic features of HIV-1 antibodies from vaccinated rhesus macaques isolated four identical neutralizing antibody (nAb) lineages across multiple animals.
